title: Effects of somatostatin, octreotide and cortistatin on ischaemic neuronal damage following permanent middle cerebral artery occlusion in the rat.
abstract: This study investigated whether peptides acting at somatostatin receptors, such as somatostatin-14, octreotide or cortistatin-14, can influence the extent of brain damage after focal ischaemia in rats. The intracerebroventricular application of 0.1 or 1.0 nmol somatostatin-14 5 min after middle cerebral artery occlusion significantly reduced the infarct size assessed 7 days after the insult (by 47% and 57% of the saline control), whereas 10.0 nmol had no significant protective effect (9% reduction). A similar dose/response relationship was obtained after intracerebroventricular injection of octreotide. The lower doses of 0.1 or 1.0 nmol afforded significant neuroprotection (reduction of the infarct size by 72 and 57%), whereas 10 nmol actually increased the infarct size up to 348%. Cortistatin-14 (10 nmol) decreased the ischaemic damage by 52%. For comparison with the neuropeptides acting on somatostatin receptors, the kappa opiate agonist enadoline (10 nmol) also had a significant protective effect against the development of focal ischaemia; the extent of the brain damage was reduced by 60% after intracerebroventricular injection.
authors.affiliation: Institute of Pharmacology and Toxicology, Otto-von-Guericke-University, Magdeburg, Germany. christine.rauca@medizin.uni-magdeburg.de
authors.forename: C
authors.initials: C
authors.lastname: Rauca
authors.forename: K
authors.initials: K
authors.lastname: Schäfer
authors.forename: V
authors.initials: V
authors.lastname: Höllt
mesh_terms: D000818:Animals; D001572:Benzofurans / Q000008:administration & dosage*; D001831:Body Temperature / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002540:Cerebral Cortex / Q000187:drug effects / Q000473:pathology; D003342:Corpus Striatum / Q000187:drug effects / Q000473:pathology; D006728:Hormones / Q000378:metabolism / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D020768:Middle Cerebral Artery; D009474:Neurons / Q000187:drug effects*; D009479:Neuropeptides / Q000378:metabolism / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000378:metabolism / Q000494:pharmacology*; D015282:Octreotide / Q000378:metabolism / Q000494:pharmacology*; D011759:Pyrrolidines / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D017473:Receptors, Opioid, kappa / Q000819:agonists; D013004:Somatostatin / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D001572:Benzofurans; D006728:Hormones; D009479:Neuropeptides; D018696:Neuroprotective Agents; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; C099323:cortistatin; D013004:Somatostatin; C067110:enadoline; D015282:Octreotide